Last reviewed · How we verify
Carbomer 980
Carbomer 980 is a Pharmaceutical excipient (polymer) Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development. Also known as: Topical vehicle gel.
Carbomer 980 acts as an inert polymer that swells in water to form viscous gels, providing structural support and controlled release properties in pharmaceutical formulations.
Carbomer 980 is a substance that has been studied in clinical trials for various conditions, including the common cold, dry eye syndrome, glaucoma, and ocular hypertension. It has been tested as a treatment in nasal and ocular applications, with studies evaluating its local tolerability and safety in healthy adult participants.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
GlaxoSmithKline is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Carbomer 980 |
|---|---|
| Also known as | Topical vehicle gel |
| Sponsor | GlaxoSmithKline |
| Drug class | Pharmaceutical excipient (polymer) |
| Modality | Small molecule |
| Phase | Phase 1 |
Mechanism of action
Carbomer 980 is not a pharmacologically active compound. It functions as a pharmaceutical excipient that cross-links when neutralized, creating a gel matrix that can suspend active ingredients, control drug release rates, and improve product stability and patient acceptability.
Approved indications
Common side effects
Key clinical trials
- Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy (NA)
- Topical Acetaminophen for Itch Relief: a Proof of Concept Study in Healthy Subjects (PHASE1, PHASE2)
- To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold (PHASE2)
- Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carbomer 980 CI brief — competitive landscape report
- Carbomer 980 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Carbomer 980
What is Carbomer 980?
How does Carbomer 980 work?
Who makes Carbomer 980?
Is Carbomer 980 also known as anything else?
What drug class is Carbomer 980 in?
What development phase is Carbomer 980 in?
Related
- Drug class: All Pharmaceutical excipient (polymer) drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Also known as: Topical vehicle gel
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing